Reuters logo
BRIEF-Ultragenyx, Kyowa Hakko Kirin announce submission of Burosumab's Biologics License Application in U.S.
2017年8月24日 / 下午12点45分 / 3 个月前

BRIEF-Ultragenyx, Kyowa Hakko Kirin announce submission of Burosumab's Biologics License Application in U.S.

Aug 24 (Reuters) - Ultragenyx Pharmaceuticals Inc:

* Ultragenyx and Kyowa Hakko Kirin announce submission of Burosumab’s Biologics License Application in the U.S.

* Ultragenyx - ‍fda will evaluate submission and will decide on whether to accept it within 60 days, at which time PDUFA action date will be set​ Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below